Sotera Health (SHC) Expected to Post Quarterly Earnings on Tuesday

Sotera Health (NASDAQ:SHC) will likely be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.2687 per share and revenue of $319.86 million for the quarter. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 9:00 AM ET.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%. The business had revenue of $321.38 million for the quarter, compared to analysts’ expectations of $309.70 million. During the same quarter in the previous year, the business posted $0.20 EPS. Sotera Health’s revenue for the quarter was up 9.2% on a year-over-year basis. On average, analysts expect Sotera Health to post $0.87 EPS for the current fiscal year and $0.95 EPS for the next fiscal year.

Sotera Health Price Performance

NASDAQ SHC opened at $18.39 on Tuesday. The business has a 50 day simple moving average of $18.56 and a 200 day simple moving average of $17.05. Sotera Health has a 52-week low of $13.09 and a 52-week high of $19.85. The company has a debt-to-equity ratio of 3.33, a quick ratio of 2.55 and a current ratio of 2.80. The stock has a market cap of $5.25 billion, a price-to-earnings ratio of 21.29 and a beta of 1.85.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SHC. Wall Street Zen raised shares of Sotera Health from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Citigroup upped their target price on shares of Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Piper Sandler reiterated an “overweight” rating and set a $25.00 target price on shares of Sotera Health in a report on Tuesday, September 8th. Weiss Ratings downgraded Sotera Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. Finally, JPMorgan Chase & Co. restated an “underweight” rating and issued a $17.00 price target on shares of Sotera Health in a report on Wednesday, October 14th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.38.

Insider Buying and Selling at Sotera Health

In other Sotera Health news, insider Michael Rutz sold 150,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the sale, the insider directly owned 334,279 shares of the company’s stock, valued at $6,297,816.36. The trade was a 30.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Michael Petras, Jr. sold 850,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the transaction, the chairman owned 3,969,393 shares of the company’s stock, valued at approximately $73,433,770.50. This represents a 17.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,294,515 shares of company stock valued at $23,999,528 in the last 90 days. 15.36% of the stock is currently owned by corporate insiders.

Sotera Health Company Profile

Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.